Screener
Ultragenyx Pharmaceutical RARE Accretion (Amortization) of Discounts and Premiums, Investments
Accretion (Amortization) of Discounts and Premiums, Investments at other companies
Other financials
Where this comes from
Reported directly by Ultragenyx Pharmaceutical in its filing.
Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.
The source filing: Ultragenyx Pharmaceutical’s 10-Q, filed May 6, 2026.
- Filed
- May 5, 2026, 8:00 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-206960
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Net loss | $(185) | $(151) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation | 30 | 40 |
| Amortization of discount on marketable securities, net | (1) | (2) |
| Depreciation and amortization | 8 | 9 |
| Non-cash royalty revenue | (20) | (19) |
| Non-cash interest expense on liabilities for sales of future royalties | 21 | 14 |
| Other | 1 | (1) |
Item 1. Financial Statements
FAQ
- What is Ultragenyx Pharmaceutical's accretion (amortization) of discounts and premiums, investments?
- Ultragenyx Pharmaceutical (RARE) reported accretion (amortization) of discounts and premiums, investments of $1M in Q1 2026.
- How has Ultragenyx Pharmaceutical's accretion (amortization) of discounts and premiums, investments changed year-over-year?
- Ultragenyx Pharmaceutical's accretion (amortization) of discounts and premiums, investments decreased by 50.0% year-over-year, from $2M to $1M.
- What is the long-term trend for Ultragenyx Pharmaceutical's accretion (amortization) of discounts and premiums, investments?
- Over 3 years (2021 to 2025), Ultragenyx Pharmaceutical's accretion (amortization) of discounts and premiums, investments has grown at a -15.4% compound annual growth rate (CAGR), from -$6.61M to $4M.
- What does accretion (amortization) of discounts and premiums, investments mean?
- This reflects the periodic adjustment to the carrying value of investment securities to account for the amortization of premiums or accretion of discounts over the life of the instrument. It reconciles the difference between the purchase price and the face value of debt securities. This metric helps investors understand the non-cash adjustments to investment income within the operating cash flow.
Ask your AI about Ultragenyx Pharmaceutical's accretion (amortization) of discounts and premiums, investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude